RJV Stock Chart & Stats
€0.20
€0.02(6.30%)
At close: 4:00 PM EST
€0.20
€0.02(6.30%)
Day’s Range― - ―
52-Week Range€0.14 - €0.49
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€32.27M
Enterprise Value€102.25M
Total Cash (Recent Filing)€17.18M
Total Debt (Recent Filing)€5.46M
Price to Earnings (P/E)―
Beta0.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)2.37
Price to Sales (P/S)0.98
P/FCF Ratio22.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.48Price Target Upside137.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
EBITDA Growth And Margin ExpansionImproving EBITDA and margins indicate stronger operating leverage from better gross margin and disciplined costs. If maintained, this provides greater capacity to fund product development, absorb regional volatility, and convert revenue growth into more durable earnings over the next several quarters.
Cash Generation And Balance SheetPositive operating cash flow and a net cash position strengthen financial flexibility while the company remains only modestly profitable at the operating level. This supports continued investment in capacity and innovation without the same balance-sheet pressure associated with higher leverage.
Manufacturing Scale And ProductivityExpanded capacity and faster production turnaround improve SomnoMed’s ability to serve growth across international markets and support customer service. These operational gains can enhance scalability and productivity, helping protect margins as volumes increase and new products are introduced.
Bears Say
Structural European Access HeadwindsEuropean reimbursement and access changes affect how patients are identified, referred, and funded, making the company’s largest region harder to grow predictably. These structural issues may require sustained commercial adaptation and could constrain revenue and margin progress over several quarters.
Net Losses And Negative ReturnsDespite improved operating profitability, continued net losses show that costs below EBIT still prevent the business from generating positive shareholder returns. Persistent negative ROE limits internally compounded growth and leaves less evidence that recent operational improvements have yet become durable bottom-line earnings.
Foreign Exchange ExposureThe heavy concentration of revenue outside the reporting currency makes reported results sensitive to Australian-dollar movements. Even when underlying regional demand is stable, adverse translation can reduce reported revenue and earnings, complicating planning and obscuring operational progress.
Somnomed Limited News
RJV FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest stock price was €0.14 and its highest was €0.49 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is €32.27M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in DE:RJV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.48%
12-Months-Change
Fundamentals
Return on Equity
-5.44%
Trailing 12-Months
Asset Growth
-2.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
RJV Company Deck
RJV Earnings Call
Q4 2026
0:00 / 0:00
RJV Stock 12 Month Forecast
Average Price Target
€0.48
▲(137.73% Upside)